Sept 1 (Reuters) - The U.S. Federal Trade Commission has allowed Amgen Inc to move ahead with its $27.8 billion deal to buy Horizon Therapeutics, CNBC reported on Friday. (Reporting by Manas Mishra in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
301 USD | +1.57% | -1.79% | +4.51% |
05-28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
05-28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.51% | 159B | |
+39.82% | 731B | |
+31.34% | 586B | |
-7.31% | 348B | |
+14.23% | 319B | |
+0.86% | 273B | |
+13.47% | 235B | |
-6.63% | 203B | |
+7.49% | 202B | |
-2.05% | 158B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- U.S. FTC allows Amgen to move forward with $27.8 bln Horizon deal - CNBC